Patients With End-Stage Renal Disease, Atrial Fibrillation Have Unique Considerations When Starting Anticoagulation Therapy

Conference|ASHP Midyear Clinical Meeting and Exhibition - American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition

Assessing stroke benefit and net clinical benefit of anticoagulation is essential in patients with end-stage renal disease and atrial fibrillation.

In an interview with Pharmacy Times, Zachary Noel, PharmD, BCCP, discussed the presentation at the American Society of Health-System Pharmacists 2021 Midyear Meeting titled "Direct Oral Anticoagulant Dilemmas: Stroke Prevention for Atrial Fibrillation in the Oldest Old and Patients with End-Stage Renal Disease."

In the interview, Noel discussed specific considerations for patients with end-stage renal disease and atrial fibrillation, recommendations for anticoagulation initiation, and how to best assess stroke risk in these populations.